Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kaltura Inc (KLTR) vs Viatris Inc (VTRS) Price & Performance

Kaltura IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Kaltura Inc vs Viatris Inc — how do they compare? Kaltura Inc trades at $1.32 (market cap $199.08M), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 100.6× Kaltura Inc's market cap, and Viatris Inc pays a 2.75% dividend while Kaltura Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kaltura Inc for 21 Days and Viatris Inc for 57 Days on average.

KLTRVTRS
Market Cap
$199.08M$20.03B
Volume
175,92714,109,977
Sector
TechnologyHealth
52-Week High
$1.89$18.27
52-Week Low
$1.08$9.74
Typical Hold Time
21 Days57 Days
Enterprise Value
$211.29M$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kaltura Inc

Kaltura (KLTR) trades at $1.305, down 1.88% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue stabilizing around $181M and net losses narrowing from -$68M in 2022 to -$12M in 2025. Recent positive developments include AI platform awards and major streaming deployments, though valuation metrics remain elevated with P/S of 1.08 and EV/EBITDA of 271.59.

The stock presents a turnaround story with improving profitability trends but faces significant execution risks. Analyst sentiment is mixed with 44% buy ratings, while technical indicators suggest near-term pressure. Key catalysts include AI product commercialization and further margin improvement, but high debt levels and persistent losses require careful monitoring.

Viatris Inc

Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.

The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KLTR
0% Buy100% Sell
Avg holding period · 21 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About Kaltura Inc

Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)

Read more on KLTR →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →